Proprietary Research

 
News Articles for Proprietary Research top ^
- IND application for Phase 1 clinical trial of IMO-9200 in healthy volunteers accepted by FDA; patient dosing on track to begin in fourth quarter CAMBRIDGE, Mass., Oct.
Sign-up for Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 investment picks
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT®) > FHACT® cervical cancer detection test has potential application for more than 2 million patients per year in the United States RUTHERFORD, N.J., Oct.
Sign-up for Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers investment picks
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today disclosed a development program for a P/neurokinin-1 (NK 1 ) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). NK 1 receptor antagonists are administered in combination with a 5-HT 3 receptor antagonist for the prevention of CINV.
Sign-up for Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV investment picks
http://media.marketwire.com/attachments/201411/291217_CellMedX_WhiteLogo_Small_FINAL.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1161566&ProfileId=051205&sourceType=1 LAS VEGAS, NV --
Sign-up for Cell MedX Corp. (CMXC), Announces Acquisition of Proprietary Technology for Treatment of Diabetes and Related Ailments investment picks
Amkor Technology, Inc. (Nasdaq: AMKR), a leading provider of semiconductor assembly and test services, today announced that it has granted GLOBALFOUNDRIES a non-exclusive license to its proprietary copper pillar wafer bump technology.
Sign-up for Amkor Technology Licenses Proprietary Copper Pillar Wafer Bump Technology to GLOBALFOUNDRIES investment picks
Agreement represents the first distributor relationship outside the mainland United States for the company's ophthalmic formulations, which are now available by prescription in 36 states and US territories SAN DIEGO , Nov.
Sign-up for Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless™ Proprietary Formulations to Ophthalmologists in Puerto Rico investment picks
Dropless Cataract Therapy now available in California, Nevada, Oregon, and Hawaii SAN DIEGO , Dec.
Sign-up for Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations to Four Key Western States investment picks
PINGDINGSHAN, China, Jan.
Sign-up for SinoCoking to Implement Proprietary Gas Compression and Blending Technology Program investment picks
-- New nonsteroidal anti-inflammatory drug (NSAID) medication used for management of mild to severe pain in adults --
Sign-up for Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject™(diclofenac sodium) Injection investment picks
ROCHESTER, N.Y. and LONDON , Dec.
Sign-up for VirtualScopics Licences IXICO's Proprietary TrialTracker™ Digital Platform investment picks
2015/1/13
Dropless Therapy™ injectable and planned LessDrops™ topical compounded formulations offer the same patent-pending technology and the promise of significantly reducing or completely eliminating the number of patient eye drop administrations.
Sign-up for Imprimis Pharmaceuticals to Highlight its Proprietary Ophthalmic Solutions at the Hawaiian Eye 2015 and the Cataract Surgery: Telling It Like It Is! Meetings investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Proprietary Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Proposed Sale  |  Next: Prospectus Supplement